GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OKYO Pharma Limited
OKYO Pharma is a biotech company developing drugs for the treatment of eye diseases. Its stock price is highly volatile and driven by news about the progress of clinical trials. The chart reflects investor expectations for the development of a new drug.
Share prices of companies in the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing treatments for inflammatory eye diseases, particularly dry eye syndrome, and chronic pain. We've classified it in the "Pharma Eyes" segment. The chart below shows the overall dynamics in the ophthalmic pharmaceutical niche, where there is a high demand for new treatments.
Broad Market Index - GURU.Markets
OKYO Pharma is a biopharmaceutical company developing treatments for inflammatory eye diseases, particularly dry eye syndrome. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how OKYO shares correlate with sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
OKYO - Daily change in the company's share price OKYO Pharma Limited
For OKYO Pharma Limited, which develops drugs for eye diseases, daily volatility reflects sensitivity to news about clinical trials. This metric is an important component in formulas that assess the risks and potential of biotech companies.
Daily change in the price of a set of shares in a market segment - Pharma eyes
For OKYO Pharma Limited, which develops drugs for eye diseases, daily volatility reflects sensitivity to news about clinical trials. This metric is an important component in formulas that assess the risks and potential of biotech companies.
Daily change in the price of a broad market stock, index - GURU.Markets
OKYO Pharma is a biotech company specializing in the treatment of eye diseases. Its share price depends on clinical trial success and regulatory approvals. These biotech-specific events create unique price movements that contribute to overall market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OKYO Pharma Limited
For OKYO Pharma Limited, year-on-year performance is a story about the development of its dry eye treatment. Its 12-month market capitalization depends entirely on progress in clinical trials. Successful data could offer patients a new approach to treating this common and debilitating condition.
Annual dynamics of market capitalization of the market segment - Pharma eyes
OKYO Pharma is a clinical-stage biotech company developing drugs for the treatment of eye diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OKYO Pharma is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of its eye drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of eye diseases. Its monthly performance is entirely dependent on news about its clinical trials. The results of its lead candidate, OK-101, are the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing new drugs for the treatment of inflammatory eye diseases and chronic pain. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its lead candidates, targeting these common problems, in trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
OKYO Pharma is a biotech company focused on treating eye diseases. Its shares are buoyed by anticipation of clinical trial results. The chart shows that the company's monthly price fluctuations are unrelated to overall market trends, but rather reflect specific scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OKYO Pharma Limited
OKYO Pharma, a clinical-stage biopharmaceutical company developing drugs for the treatment of eye diseases, exhibits high volatility. Weekly stock performance is driven by news about clinical trials, reflecting the risks and potential of the large ophthalmology market.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
OKYO Pharma develops medications for dry eye and chronic pain. These are large, highly competitive markets. The chart shows how the company's stock performance compares to the ophthalmology sector, allowing you to assess whether its developments distinguish it from other players.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OKYO Pharma is a clinical-stage biotech company. Its shares exist in a world of their own, where research data is king. The chart clearly demonstrates that OKYO's performance is largely uncorrelated with the market, moving based on its own unique news.
Market capitalization of the company, segment and market as a whole
OKYO - Market capitalization of the company OKYO Pharma Limited
OKYO Pharma's chart is a financial map of the fight against dry eye. This biotech company's market cap reflects the hopes for its drug for this common condition. Its dynamics are a barometer of progress in clinical trials and potential in the huge market where millions of people seek effective relief.
OKYO - Share of the company's market capitalization OKYO Pharma Limited within the market segment - Pharma eyes
OKYO Pharma's position in ophthalmology is driven by the development of new treatments for dry eye and eye pain. Its market share reflects the potential of its lead drug candidate, which addresses widespread problems affecting millions of people worldwide.
Market capitalization of the market segment - Pharma eyes
OKYO Pharma is a biotech company developing drugs for the treatment of eye diseases. The chart below shows the overall market capitalization of the entire pharmaceutical industry. Its dynamics provide the backdrop against which OKYO is attempting to carve out its niche in ophthalmology.
Market capitalization of all companies included in a broad market index - GURU.Markets
OKYO Pharma is a biopharmaceutical company developing treatments for dry eye syndrome and chronic pain. Its market capitalization reflects the potential of its research and development. The chart below shows the economic weight of companies solving common problems.
Book value capitalization of the company, segment and market as a whole
OKYO - Book value capitalization of the company OKYO Pharma Limited
For OKYO Pharma, a biopharmaceutical company, book value represents its R&D capital. The chart below shows its financial resources for developing eye disease drugs. This level is an indicator of its ability to finance its preclinical and clinical programs.
OKYO - Share of the company's book capitalization OKYO Pharma Limited within the market segment - Pharma eyes
OKYO Pharma is a clinical-stage biotech company developing drugs for the treatment of eye diseases. Its value lies in its scientific platform. Its share of tangible assets will be minimal, which is typical for R&D companies whose main capital is intellectual property.
Market segment balance sheet capitalization - Pharma eyes
OKYO Pharma is a clinical-stage biotech company. Its value is created in laboratories developing drugs for eye diseases. This is a "light" model. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
OKYO Pharma's balance sheet is focused on developing drugs for dry eye and chronic pain. The book value chart shows the amount of financial resources devoted to addressing these common conditions, where there is a significant need for new, effective therapies.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OKYO Pharma Limited
OKYO Pharma is a biotech company developing treatments for dry eye and chronic pain. It has no tangible assets. Its market capitalization is a bet on its scientific research. The chart shows the high volatility typical of early-stage biotechs, whose value depends on news from the lab.
Market to book capitalization ratio in a market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of eye diseases. The company has no commercial products. Its market capitalization is a bet on the success of its research. The chart shows the premium investors pay for the hope of developing a new drug.
Market to book capitalization ratio for the market as a whole
OKYO Pharma is a biotech company developing drugs to treat inflammatory eye diseases. The chart shows how the market values the company, which is targeting a large and growing market. Its market capitalization is a bet on the success of its clinical trials and the potential of its drugs to improve the lives of patients with dry eye syndrome.
Debts of the company, segment and market as a whole
OKYO - Company debts OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs to treat eye diseases such as dry eye syndrome. Debt is a way for such a company to finance expensive and time-consuming clinical trials before approval and market launch.
Market segment debts - Pharma eyes
OKYO Pharma is a clinical-stage biopharmaceutical company specializing in the treatment of inflammatory eye diseases. Developing ophthalmic drugs is a lengthy and expensive process. The chart shows the general financial parameters for the biotech sector, against which OKYO is raising capital to conduct clinical trials and bring its product to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OKYO Pharma Limited
OKYO Pharma is a biotech company specializing in drugs for the treatment of ophthalmic diseases such as dry eye syndrome. Developing ophthalmic drugs is a lengthy and expensive process. This chart shows the proportion of its R&D funding that comes from debt, a key indicator of financial risk for investors.
Market segment debt to market segment book capitalization - Pharma eyes
OKYO Pharma's development of eye treatments targets a large and aging market. This chart illustrates how the biotech sector as a whole funds its research. It allows one to understand OKYO's financial model and its reliance on external capital to conduct expensive ophthalmology clinical trials.
Debt to book value of all companies in the market
OKYO Pharma develops drugs for the treatment of dry eye and chronic pain. Pharmaceutical research, even in narrow niches, requires significant and long-term financing. The chart helps put their debt burden into perspective in the biopharmaceutical sector as a whole.
P/E of the company, segment and market as a whole
P/E - OKYO Pharma Limited
This chart shows the valuation of OKYO Pharma, a clinical-stage biopharmaceutical company specializing in the treatment of eye diseases. Its value is determined not by current profits, but by the potential of its developments to become new treatments for common conditions like dry eye syndrome.
P/E of the market segment - Pharma eyes
This metric represents the average valuation for the biotech sector in which OKYO Pharma operates. In this industry, filled with research-stage companies, the average earnings estimate is often uninformative. However, it does reflect the overall level of investor optimism regarding eye disease treatments.
P/E of the market as a whole
OKYO Pharma is a biopharmaceutical company developing drugs to treat inflammatory eye diseases such as dry eye syndrome. It's a large and competitive market. This chart shows sentiment in the pharmaceutical sector. It helps understand how the market assesses OKYO Pharma's chances of competing with existing treatments and how news about clinical trials impacts its valuation.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OKYO Pharma Limited
OKYO Pharma is a biotech company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. Its future depends on the success of clinical trials of its lead candidate. This chart reflects investor expectations regarding the potential of its nonsteroidal anti-inflammatory drug in the large and competitive ophthalmology market.
%20P%2FE%20OKYO%20Pharma%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OKYO-Pharma-Limited&v=1772702221432 "Chart of the company's future (projected) P/E OKYO Pharma Limited")
Future (projected) P/E of the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. This chart reflects expectations for the biotech sector, providing context for assessing the market's perception of this highly specialized area of ophthalmology and the potential of OKYO's developments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772702221432 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
OKYO Pharma is a biopharmaceutical company developing drugs to treat inflammatory eye diseases such as dry eye syndrome. This chart of overall expectations reflects investor sentiment toward the biotech. Market optimism facilitates raising capital for clinical trials aimed at addressing common ophthalmological conditions affecting millions of people.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772702221433 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of dry eye and chronic pain. This chart shows the financial costs of advancing candidates through clinical trials. Future profitability depends entirely on the success of these studies and the potential launch of these products.
Profit of companies in the market segment - Pharma eyes
Data Storage Corporation provides cloud storage, backup, and disaster recovery services. Profitability in this sector depends on the growth of data volumes and competition from cloud giants. This chart shows how demand for data security and availability creates a stable market, but pricing pressure from large providers poses a challenge.
Overall market profit
OKYO Pharma is a biotech company developing drugs for the treatment of dry eye and chronic pain. Currently in clinical development, its value is determined by the potential of its lead candidates. This is an example of a business that can radically change its trajectory after successful trials, regardless of the overall economic situation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OKYO Pharma Limited
OKYO Pharma is a biotech company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. Its profit outlook is long-term and depends on the success of clinical trials. This chart shows analyst expectations regarding the vast dry eye market and the potential of OKYO.
%20profit%20of%20the%20company%20OKYO%20Pharma%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OKYO-Pharma-Limited&v=1772702221446 "Graph of future (projected) profit of the company OKYO Pharma Limited")
Future (predicted) profit of companies in the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, such as dry eye syndrome, and chronic pain. This chart shows profitability forecasts for the pharmaceutical sector. It reflects the significant need for new treatments for common conditions that significantly reduce patients' quality of life.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772702221451 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
OKYO Pharma is a pharmaceutical company developing treatments for eye diseases such as dry eye. Demand for its potential products will be driven by medical needs. However, the overall profit forecast shown in this chart impacts the investment environment, which affects funding for clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772702221484 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OKYO Pharma Limited
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. Currently in the clinical stage, it has no commercial revenue. The chart reflects investor confidence in the potential of its drug candidates to capture share in the large and growing ophthalmology market.
P/S market segment - Pharma eyes
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, such as dry eye syndrome, and chronic pain. This chart shows the average valuation in the sector, allowing one to assess the market's perception of OKYO's ophthalmology revenue potential.
P/S of the market as a whole
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. The company is in clinical trials. This chart, reflecting the average estimated real revenue, clearly highlights how biotech investments are betting on scientific breakthroughs in ophthalmology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OKYO Pharma Limited
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. This chart reflects investor expectations for the future commercial potential of its lead candidate. The assessment is based on expectations for successful completion of clinical trials and market entry.
%20P%2FS%20OKYO%20Pharma%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OKYO-Pharma-Limited&v=1772702221543 "The graph of the company's future (projected) P/S OKYO Pharma Limited")
Future (projected) P/S of the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, such as dry eye syndrome, and chronic pain. The chart shows how the market estimates OKYO's future sales, reflecting the potential of its developments to address significant unmet medical needs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772702221746 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Investor optimism about future revenue depends on progress in treating common conditions such as dry eye. OKYO Pharma is developing drugs to address this and other inflammatory conditions. Given the huge number of people suffering from these conditions, a successful launch of a new drug could generate significant revenue and support growth in the pharmaceutical sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772702221809 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company focused on developing treatments for dry eye and chronic pain. Currently, the company has no commercial products, and its financial curve reflects not sales revenue but rather the funding stages of its research and development in anticipation of future success.
Sales of companies in the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs to treat inflammatory eye diseases, particularly dry eye syndrome. This chart shows the company's total ophthalmology revenue. It illustrates the large and growing market for common eye diseases, where OKYO aims to offer a new treatment approach.
Overall market sales
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, such as dry eye syndrome, and neuropathic corneal pain. Its prospects depend on the success of clinical trials. This overall economic outlook influences investment interest in biotech companies targeting large markets.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OKYO Pharma Limited
OKYO Pharma is a biopharmaceutical company developing treatments for dry eye syndrome and chronic pain. Its future depends on the results of clinical trials. The chart shows analysts' speculative revenue forecasts, which are a bet on the company's ability to offer an effective solution for these common conditions.
%20sales%20of%20the%20company%20OKYO%20Pharma%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OKYO-Pharma-Limited&v=1772702221990 "Schedule of future (projected) sales of the company OKYO Pharma Limited")
Future (projected) sales of companies in the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing treatments for dry eye syndrome and chronic pain. Its lead candidate targets the inflammation underlying these conditions. This chart displays projected sales for the entire ophthalmology pharmaceutical segment, demonstrating overall growth expectations for this therapeutic market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772702222212 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
OKYO Pharma is a biopharmaceutical company developing treatments for dry eye and chronic pain. The company is currently in clinical trials, and its future depends on their success. This overall economic activity schedule impacts the investment climate in the biotech sector, which affects the company's ability to finance its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772702222323 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OKYO Pharma Limited
OKYO Pharma is a biotechnology company developing drugs for the treatment of inflammatory eye diseases. This metric is a financial reflection of its scientific activity. It demonstrates the amount of investment in clinical trials required to bring a new drug to market and achieve commercial success in ophthalmology.
Market segment marginality - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases and chronic pain. Being in the clinical stage, its financial performance reflects its investment in R&D. This chart provides an overview of the company's operating model compared to other ophthalmology companies.
Market marginality as a whole
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, such as dry eye syndrome. Their approach is aimed at modulating lipid mediators. Their success depends on trial results. This overall profitability curve doesn't affect their scientific work, but it is important for attracting investment.
Employees in the company, segment and market as a whole
Number of employees in the company OKYO Pharma Limited
OKYO Pharma is a clinical-stage biopharmaceutical company developing drugs to treat ophthalmic diseases such as dry eye syndrome. Its team is small. This chart shows the dynamics of the small team of scientists and managers leading development in this highly specialized area of ophthalmology.
Share of the company's employees OKYO Pharma Limited within the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases. This chart shows the percentage of ophthalmologists and scientists the company attracts. Its small but focused team is working on developing new drops for the treatment of dry eye syndrome.
Number of employees in the market segment - Pharma eyes
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases and chronic pain. This chart shows overall occupancy in the ophthalmology sector. It illustrates how the company is targeting large markets with significant unmet needs for new, more effective treatments.
Number of employees in the market as a whole
OKYO Pharma is a biopharmaceutical company developing drugs to treat inflammatory eye diseases, particularly dry eye syndrome. This is a common problem requiring new solutions. This graph illustrates the labor market, where the healthcare sector is constantly in need of specialists. OKYO is creating demand for ophthalmologists and immunologists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OKYO Pharma Limited (OKYO)
OKYO Pharma Limited is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases and chronic pain. This chart is a classic example of a biotech company. The high market capitalization per employee suggests that the market is not evaluating current operations, but the potential of drugs being developed by a small scientific team.
%20of%20the%20company%20OKYO%20Pharma%20Limited%20(OKYO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OKYO-Pharma-Limited-OKYO&v=1772702222816 "Chart of market capitalization per employee (in thousands of dollars) of the company OKYO Pharma Limited (OKYO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
OKYO Pharma is a biotech company developing drugs for the treatment of inflammatory eye diseases and chronic pain. Their valuation is based on clinical development potential. This metric reflects how the market values their scientific approach relative to their team. A high valuation reflects investors' expectations for the development of a marketable and successful product.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772702222836 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
OKYO Pharma Limited is a clinical-stage biopharmaceutical company developing drugs for the treatment of dry eye and chronic pain. Its valuation is contingent on success in clinical trials. This metric reflects the typical dynamics of biotech, where a small team is working on a product for a huge potential market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772702222842 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OKYO Pharma Limited (OKYO)
OKYO Pharma is a preclinical biotech R&D company developing drugs for the treatment of inflammatory eye diseases (dry eye syndrome) and chronic pain. This chart reflects their early stage: it shows the net loss (research expenses) per employee.
%20Chart%20OKYO%20Pharma%20Limited%20(OKYO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OKYO-Pharma-Limited-OKYO&v=1772702223016 "Company Profit Per Employee (in thousands of dollars) Chart OKYO Pharma Limited (OKYO)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
OKYO Pharma is a clinical-stage biopharmaceutical company focused on treating eye diseases. As with other R&D firms, this timeline is a goal for the future. Currently, all value lies in the intellectual potential of their research team. A successful drug will allow them to generate profits above the industry average.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772702223024 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
OKYO Pharma (OKYO) is a clinical-stage biopharmaceutical company specializing in drugs for dry eye and chronic pain. This is R&D. This chart shows the typical biotech picture: negative profit per employee, as all resources are invested in clinical trials to obtain approval.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772702223042 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OKYO Pharma Limited (OKYO)
For OKYO Pharma, a company developing medications to treat eye diseases such as dry eye syndrome, this graph reflects the clinical trial stage. Future commercial success and revenue growth per employee depend on the research results and approval of its eye drops.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OKYO-Pharma-Limited-OKYO&v=1772702223045 "Sales chart per company employee OKYO Pharma Limited (OKYO)")
Sales per employee in the market segment - Pharma eyes
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases (dry eye syndrome) and chronic pain. This is R&D. This metric reflects the average revenue per employee in the segment. It allows us to assess how productive their R&D team is in their niche compared to other ophthalmology biotechs.
Sales per employee for the market as a whole
OKYO Pharma (OKYO) is a clinical-stage biopharmaceutical company developing drugs for the treatment of dry eye and chronic pain. Currently, its staff consists entirely of researchers. This metric is critical for OKYO: it's at zero. Future growth will indicate the success of their R&D and the receipt of partner fees.
Short shares by company, segment and market as a whole
Shares shorted by company OKYO Pharma Limited (OKYO)
OKYO Pharma is a very early-stage biotech developing drugs for dry eye and chronic pain. This chart reflects the high investor skepticism typical of biotech "penny stocks": investors are betting that its preclinical programs will never succeed in the clinic and that the company is burning through capital.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OKYO-Pharma-Limited-OKYO&v=1772702223048 "Short Shares Chart for the Company OKYO Pharma Limited (OKYO)")
Shares shorted by market segment - Pharma eyes
OKYO Pharma (OKYO) is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases, particularly dry eye syndrome. This chart shows the overall short position in the ophthalmic pharmaceutical sector. It reflects the high failure rate and fierce competition in developing an effective dry eye treatment.
Shares shorted by the overall market
OKYO Pharma is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing OKYO will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OKYO Pharma Limited (OKYO)
This oscillator for OKYO Pharma is a binary betting indicator for dry eye treatment. It's a huge market, and the company is developing new drops for its treatment. Positive news about progress in Phase 2 clinical trials is causing a sharp "overheating" (above 70). Any delays, mixed results, or the need to raise capital immediately send the stock into "oversold" territory (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OKYO-Pharma-Limited-OKYO&v=1772702223052 "RSI 14 indicator chart for the company's stock OKYO Pharma Limited (OKYO)")
RSI 14 Market Segment - Pharma eyes
OKYO Pharma (OKYO) is a biotech eye-hunter. They develop drugs to treat dry eye syndrome (DED) and eye pain. The "Pharma eyes" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is OKYO's growth due to their R&D, or is the entire biotech sector simply overheated?
RSI 14 for the overall market
OKYO Pharma (OKYO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OKYO (OKYO Pharma Limited)
OKYO Pharma is a clinical-stage biopharmaceutical company developing a lipid-based drug for the treatment of dry eye syndrome (DED) and neuropathic eye pain. This chart shows the speculative average price target from analysts based on their confidence in this R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OKYO-OKYO-Pharma-Limited&v=1772702223065 "A chart showing analyst consensus forecasts for the expected stock price. OKYO (OKYO Pharma Limited)")
The difference between the consensus estimate and the actual stock price OKYO (OKYO Pharma Limited)
OKYO - OKYO Pharma is a biotech company developing drugs for the treatment of inflammatory eye diseases (dry eye syndrome) and chronic pain. This chart clearly demonstrates the upside and downside potential analysts see in the stock. It measures the gap between the price and forecast, reflecting their confidence in the company's R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OKYO-OKYO-Pharma-Limited&v=1772702223087 "A chart showing the difference between the consensus forecast and the actual stock price. OKYO (OKYO Pharma Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
OKYO Pharma (OKYO) is a biotech company developing drugs for the treatment of dry eye syndrome and neuropathic eye pain. This chart shows general expectations for the ophthalmology sector. It reflects whether experts believe the market for treating eye diseases caused by screen time will grow.
Analysts' consensus forecast for the overall market share price
OKYO Pharma is a biotech company developing drugs to treat dry eye and chronic pain. This chart shows overall risk appetite. For OKYO, a high-risk clinical-stage company, overall market optimism is critical to raising the capital needed to fund lengthy and expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OKYO Pharma Limited
OKYO Pharma (OKYO) is a pre-clinical biotech company. Their specialty is dry eye. They are developing new lipid-based drops to treat this huge but complex market. This graph is an R&D bet. Its valuation is a lottery ticket: the market's faith in their (very early) science and their ability to compete with the giants (AbbVie, Bausch).
AKIMA Market Segment Index - Pharma eyes
OKYO Pharma is a biotech company specializing in the development of drugs for the treatment of inflammatory eye diseases (dry eye syndrome) and chronic pain. This chart shows the average index for the pharmaceutical sector. It helps investors assess how OKYO, with its focus on ophthalmology, compares to the average.
The AKIM Index for the overall market
OKYO Pharma is a biopharmaceutical company developing drugs for the treatment of inflammatory eye diseases (dry eye). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, in its clinical trials stage, compares to the overall economic trends affecting the healthcare sector.
